Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Дапаглифлозин и сердечно-сосудистые исходы при сахарном диабете 2-го типа
2018-11-10
SCID: 54.1/mb7zsvfv
Discuss with AI
DapagliflozinHeart failure hospitalizationMajor adverse cardiovascular eventsRenal outcomesSGLT2 inhibitor
Figures from the paper
Abstract (AI)
BACKGROUND: The cardiovascular safety profile of dapagliflozin, a selective inhibitor of sodium-glucose cotransporter 2 that promotes glucosuria in patients with type 2 diabetes, is undefined. METHODS: of body-surface area, new end-stage renal disease, or death from renal or cardiovascular causes) and death from any cause. RESULTS: We evaluated 17,160 patients, including 10,186 without atherosclerotic cardiovascular disease, who were followed for a median of 4.2 years. In the primary safety outcome analysis, dapagliflozin met the prespecified criterion for noninferiority to placebo with respect to MACE (upper boundary of the 95% confidence interval [CI], <1.3; P<0.001 for noninferiority). In the two primary efficacy analyses, dapagliflozin did not result in a lower rate of MACE (8.8% in the dapagliflozin group and 9.4% in the placebo group; hazard ratio, 0.93; 95% CI, 0.84 to 1.03; P=0.17) but did result in a lower rate of cardiovascular death or hospitalization for heart failure (4.9% vs. 5.8%; hazard ratio, 0.83; 95% CI, 0.73 to 0.95; P=0.005), which reflected a lower rate of hospitalization for heart failure (hazard ratio, 0.73; 95% CI, 0.61 to 0.88); there was no between-group difference in cardiovascular death (hazard ratio, 0.98; 95% CI, 0.82 to 1.17). A renal event occurred in 4.3% in the dapagliflozin group and in 5.6% in the placebo group (hazard ratio, 0.76; 95% CI, 0.67 to 0.87), and death from any cause occurred in 6.2% and 6.6%, respectively (hazard ratio, 0.93; 95% CI, 0.82 to 1.04). Diabetic ketoacidosis was more common with dapagliflozin than with placebo (0.3% vs. 0.1%, P=0.02), as was the rate of genital infections that led to discontinuation of the regimen or that were considered to be serious adverse events (0.9% vs. 0.1%, P<0.001). CONCLUSIONS: In patients with type 2 diabetes who had or were at risk for atherosclerotic cardiovascular disease, treatment with dapagliflozin did not result in a higher or lower rate of MACE than placebo but did result in a lower rate of cardiovascular death or hospitalization for heart failure, a finding that reflects a lower rate of hospitalization for heart failure. (Funded by AstraZeneca; DECLARE-TIMI 58 ClinicalTrials.gov number, NCT01730534 .).
Key Findings
1
Dapagliflozin did not significantly reduce MACE compared with placebo: 8.8% versus 9.4% (hazard ratio, 0.93; P=0.17).
2
Dapagliflozin reduced cardiovascular death or hospitalization for heart failure, driven by fewer heart-failure hospitalizations (hazard ratio, 0.73), without reducing cardiovascular death.
3
Dapagliflozin reduced renal events compared with placebo: 4.3% versus 5.6% (hazard ratio, 0.76), while all-cause mortality did not differ significantly.
4
Diabetic ketoacidosis and serious or discontinuation-causing genital infections were more frequent with dapagliflozin than placebo.
5
In 17,160 patients with type 2 diabetes, dapagliflozin met the prespecified criterion for cardiovascular safety noninferiority versus placebo for MACE.
Research Object
Dapagliflozin treatment in patients with type 2 diabetes (DECLARE‑TIMI 58 trial population)
Research Subject
Cardiovascular, renal, mortality, and safety outcomes of dapagliflozin compared with placebo, including MACE and hospitalization for heart failure
Publication Details
Publication Date
2018-11-10
Journal
Publisher
ISSN
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai4
2013 ACCF/AHA Guideline for the Management of Heart Failure2013
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes2015
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure2016
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes2017